Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation

Executive Summary

German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.

You may also be interested in...



Japan Earnings Highlights: Takeda, Astellas And Eisai

Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.

New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines

A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.

Prices Could Be Slashed Under U.K.’s New Drug-Pricing Scheme

Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel